Endocrinology, Vol 127, 567-572, Copyright © 1990 by Endocrine Society

ARTICLES

Changes in anterior pituitary hormone levels after serotonin 1A receptor stimulation

A Di Sciullo, MT Bluet-Pajot, F Mounier, C Oliver, B Schmidt and C Kordon
U.159 INSERM, Paris, France.

Although the role of serotonin (5HT) in the regulation of anterior pituitary hormone secretion is well documented, the involvement of specific 5HT receptor subtypes in this action is not yet fully elucidated. In the present work we attempted to determine the neuroendocrine role of the 5HT1A receptor subtype. This was chosen mainly because highly selective pharmacological tools are available for that subtype. 8-Hydroxy-2-(di-n-propylamino)tetralin (8OHDPAT) and ipsapirone were injected iv in conscious, freely moving male rats cannulated in the jugular vein. For the sake of comparison, a 5HT receptor agonist with preference for the 5HT1B and 5HT1C receptor subtypes 1-(m-trifluoromethyl-phenyl)piperazine (TFMPP) was also administered. Plasma PRL, ACTH, and beta-endorphin levels increased in a dose-dependent manner after 8-OHDPAT (0.01-1 mg/kg) or ipsapirone (0.5-7.5 mg/kg) injection. Maximal effects were obtained between 7-15 min. Only the highest dose of 1-(m-trifluoromethyl-phenyl)piperazine (5 mg/kg) resulted in the same response. In contrast, none of the drugs used affected plasma GH, TSH, or LH levels at any dose tested. The results indicate that 5HT1A receptors are involved in the regulation of PRL as well as ACTH and beta-endorphin secretion. 8OHDPAT was almost 40 times more potent than ipsapirone. The maximal effects of the two drugs on PRL release were comparable. In contrast, ipsapirone behaved as a partial agonist only on ACTH and beta-endorphin secretion, thus suggesting that different neuronal targets are involved in the stimulation of the three hormones by 5HT.

This article has been cited by other articles:

				Q. Li, C. Wichems, A. Heils, L. D. Van de Kar, K.-P. Lesch, and D. L. Murphy Reduction of 5-Hydroxytryptamine (5-HT)1A-Mediated Temperature and Neuroendocrine Responses and 5-HT1A Binding Sites in 5-HT Transporter Knockout Mice J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 999 - 1007. [Abstract] [Full Text]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				L. D. V. d. Kar, Q. Li, T. M. Cabrera, M. S. Brownfield, and G. Battaglia Alterations in 8-Hydroxy-2-(dipropylamino)tetralin-Induced Neuroendocrine Responses after 5,7-Dihydroxytryptamine-Induced Denervation of Serotonergic Neurons J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 256 - 262. [Abstract] [Full Text]

				J. De Vry, R. Schohe-Loop, H.-G. Heine, J. M. Greuel, F. Mauler, B. Schmidt, H. Sommermeyer, and T. Glaser Characterization of the Aminomethylchroman Derivative BAY × 3702 as a Highly Potent 5-Hydroxytryptamine1A Receptor Agonist J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1082 - 1094. [Abstract] [Full Text]

				C. L. Parks and T. Shenk The Serotonin 1a Receptor Gene Contains a TATA-less Promoter that Responds to MAZ and Sp1 J. Biol. Chem., February 23, 1996; 271(8): 4417 - 4430. [Abstract] [Full Text] [PDF]